QDEL

QuidelOrtho Corporation ( QDEL ) Q3 2026 Earnings Call November 3, 2026 5:00 PM EST Company Participants Sanjeev Sharma Brian Blaser - President, CEO & Director Micah Young - Chief Financial Officer & Principal Financial Officer Conference Call Participants William Bonello - Craig-Hallum Capital Group LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division Jack Meehan - Operon Research, LLC Casey Woodring - JPMorgan Chase & Co, Research Division Presentation Operator Welcome to the QuidelOrtho Third Quarter 2026 Financial Results Conference Call and webcast. [Operator Instructions] Please note, this conference call is being recorded.

― Growth in Labs and Immunohematology Outside of China Highlights Underlying Business Strength ― ― New Cost Transformation and Enterprise Restructuring Program Expected to Deliver Over $80 Million in Annual Savings in 2027 ― ― Updated Full-Year 2026 Financial Guidance Narrowing Prior Ranges ― SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a leading global provider of diagnostic solutions, today announced financial results for the third quarter ended September 27, 2026. Key Third Quarter 2026 Results: (all comparisons are to the prior year period) Total revenue was $619 million, a decrease of 12% both as reported and in constant currency.

SAN DIEGO, Oct. 29, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 62 of its Science Bytes podcast, exploring best practices in AI and informatics to make lab operations smoother.  Laboratories are facing increasing complexity and growing testing demand.

SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of diagnostic solutions, announced today that it will issue a press release to report its financial results for the third quarter 2026 ended September 27, 2026, shortly after the market closes at 4:00 p.m. ET on Tuesday, November 3, 2026.

QDEL's strong Q2 results, diversified product portfolio and cost-saving initiatives bolster its growth prospects despite persistent weakness in respiratory demand.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of diagnostic solutions, has appointed Sanjeev Sharma, CFA, as Vice President, Investor Relations, effective September 28, 2026. Mr. Sharma brings more than 20 years of experience across investor relations, corporate strategy and equity research at global organizations.

SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, is proud to share episode 61 of its Science Bytes podcast, highlighting key insights about lowering sepsis rates in the emergency room.

SAN DIEGO, Aug. 27, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 60 of its Science Bytes podcast, featuring highlights from the 2026 Association for Diagnostics and Laboratory Medicine (ADLM) Annual Conference. Hosted by Stephanie Kleewein, the special episode showcases three presentations addressing some of healthcare's most pressing challenges: delivering faster molecular diagnostic results, improving antibiotic stewardship and accelerating cardiovascular assessment.

QuidelOrtho's 2026 outlook cut highlights deeper China and respiratory risks, while cash use and rising debt add pressure despite resilient core growth.